Seer, Inc. (SEER): Results of Operations and Financial Condition
Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0001726445-ex99_1.htm EX-99.1 EX-99.1 Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook REDWOOD CITY, Calif. – August 11, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbias
How this was made
The 30-second read
Why it matters
Traders can update models using the reported revenue, gross margin, operating expense trend, net loss, free cash flow, and cash/investment balance, and reassess risk around sales-cycle elongation and macro headwinds. The IP enforcement actions add a separate catalyst stream that may influence expectations for future competitive and licensing outcomes.
Market read
Fresh quarterly financials and reiterated FY revenue range are the primary drivers, with IP enforcement developments as secondary catalysts.
What to watch
The ITC investigation initiation and the European Patent Office decision are potentially meaningful IP catalysts that could improve competitive positioning even if near-term revenue is pressured.
Background
This is Seer’s SEC Form 8-K (Item 2.02) with Q2 2026 results, cash position, and reaffirmed full-year 2026 revenue guidance, plus IP enforcement updates.
Ticker impact
Seer reported Q2 2026 revenue of $3.1M (down 23% YoY) and reaffirmed full-year 2026 revenue guidance of $16M to $18M.
Likely near-term downside bias if investors focus on YoY revenue decline and negative free cash flow, partially offset by cash balance and guidance reaffirmation.
The filing includes concrete datapoints: revenue decline, net loss, free cash flow of about negative $25.3M for six months, and cash/investments of about $209.5M, plus an unchanged FY revenue range.
Market effects
Reinforces ongoing funding and sales-cycle pressure in academic and government proteomics spending, a read-through for similar research-instrument vendors.
Limited, primarily US-listed biotech and life-science tools sentiment.
Moderate, given the ITC investigation and European patent office outcome, which can affect cross-border IP enforcement expectations.
Counterpoint
Investors may look past the YoY revenue decline to the reaffirmed FY range and sizable cash balance, treating the quarter as a temporary macro-driven trough.
Key entities
- companySeer, Inc.
Nasdaq-listed proteomics instrumentation and analytics company reporting Q2 2026 results and reaffirming FY 2026 revenue guidance.
- regulatorU.S. International Trade Commission
Opened an investigation into Nanomics’ importation of products believed to infringe Seer’s patents.
- regulatorEuropean Patent Office
Concluded that a Brigham and Women’s Hospital patent exclusively licensed by Seer will be maintained.
- companyNanomics Biotechnology Co., Ltd.
Named as the respondent in Seer’s initiated IP enforcement action before the ITC.
